Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Assets (2018 - 2025)

Silence Therapeutics' Non-Current Assets history spans 8 years, with the latest figure at $12.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 16.27% to $12.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.8 million, a 16.27% decrease, with the full-year FY2025 number at $12.8 million, down 16.27% from a year prior.
  • Non-Current Assets hit $12.8 million in Q4 2025 for Silence Therapeutics, down from $13.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SLN hit a ceiling of $16.7 million in Q2 2025 and a floor of $12.5 million in Q3 2022.
  • Historically, Non-Current Assets has averaged $14.0 million across 5 years, with a median of $13.3 million in 2022.
  • Biggest five-year swings in Non-Current Assets: rose 25.26% in 2023 and later fell 16.27% in 2025.
  • Tracing SLN's Non-Current Assets over 5 years: stood at $13.3 million in 2021, then fell by 4.58% to $12.7 million in 2022, then increased by 25.26% to $15.9 million in 2023, then dropped by 3.9% to $15.3 million in 2024, then fell by 16.27% to $12.8 million in 2025.
  • Business Quant data shows Non-Current Assets for SLN at $12.8 million in Q4 2025, $13.2 million in Q3 2025, and $16.7 million in Q2 2025.